Literature DB >> 26242852

[Retinal vein occlusion: Therapy of retinal vein occlusion].

N Feltgen1, A Pielen.   

Abstract

Treatment of retinal vein occlusion can be systemic or local. Therapeutic strategies include improved blood supply, treatment of the vision-reducing macular edema by intravitreal injection of inhibitors of vascular endothelial growth factors (VEGF) or corticosteroids and laser photocoagulation for neovascular complications. As long as head-to-head studies comparing steroids and VEGF inhibitors have not been published, none of the available intravitreally injected substances can be given priority. Well-known side effects of intravitreal steroids are cataract formation and ocular hypertension whereas VEGF inhibitors need to be frequently injected. Although therapy for retinal vein occlusion is protracted, initial long-term data indicate that treatment can be terminated in at least half of the patients . Finally, a treatment recommendation according to the current state of data is presented.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26242852     DOI: 10.1007/s00347-015-0115-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  36 in total

1.  Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.

Authors:  Peter A Campochiaro; Charles C Wykoff; Michael Singer; Robert Johnson; Dennis Marcus; Linda Yau; Gary Sternberg
Journal:  Ophthalmology       Date:  2014-07-21       Impact factor: 12.079

2.  Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.

Authors:  David L J Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-03-17       Impact factor: 12.079

3.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

4.  [Changes in hemorheologic and physiologic coagulation parameters in different methods of therapy of retinal vascular disorders--a randomized double-blind study].

Authors:  A Heinen; R Brunner; V Hossmann; W Konen; K Roll; T Wawer
Journal:  Fortschr Ophthalmol       Date:  1984

5.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2011-08       Impact factor: 12.079

6.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

7.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

8.  Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design.

Authors:  Martin A Leitritz; Faik Gelisken; Focke Ziemssen; Peter Szurman; Karl U Bartz-Schmidt; Gesine B Jaissle
Journal:  Br J Ophthalmol       Date:  2012-11-15       Impact factor: 4.638

9.  Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study.

Authors:  S Wolf; O Arend; B Bertram; A Remky; K Schulte; K J Wald; M Reim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-01       Impact factor: 3.117

Review 10.  Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Authors:  Amelie Pielen; Nicolas Feltgen; Christin Isserstedt; Josep Callizo; Bernd Junker; Christine Schmucker
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

View more
  3 in total

1.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

2.  [Incidence of retinal vein occlusion during the football World Cup in 2014 : A database analysis].

Authors:  F Lob; K Kortüm; M Müller; J Märtz; S Leicht; K Prause; S Priglinger; T Kreutzer
Journal:  Ophthalmologe       Date:  2016-09       Impact factor: 1.059

3.  Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.

Authors:  Amelie Pielen; Anima Desiree Bühler; Sonja Ute Heinzelmann; Daniel Böhringer; Thomas Ness; Bernd Junker
Journal:  J Ophthalmol       Date:  2017-07-30       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.